Skip to main content
Roche Holding AG logo

Roche Holding AG — Investor Relations & Filings

Ticker · RO ISIN · CH0012032048 LEI · 549300U41AUUVOAAOB37 SW Manufacturing
Open in API
Filings indexed 42 across all filing types
Latest filing 2016-09-02 Annual Report
Country CH Switzerland
Listing SW RO

About Roche Holding AG

https://www.roche.com/

Roche Holding AG is a global healthcare company focused on advancing science to improve health outcomes. The company operates through two primary divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals division discovers, develops, and manufactures innovative medicines across major therapeutic areas, including oncology, immunology, infectious diseases, ophthalmology, and neuroscience. The Diagnostics division provides a comprehensive portfolio of in-vitro diagnostic tests, instruments, and digital solutions that aid in the prevention, diagnosis, and monitoring of diseases. By combining its strengths in both pharmaceuticals and diagnostics, Roche aims to deliver personalized healthcare solutions that address unmet medical needs for patients worldwide.

Recent filings

Filing Released Lang Actions
Jahresabschluss zum Geschäftsjahr vom 01.01.2015 bis zum 31.12.2015
Annual Report Classification · 100% confidence The document is a comprehensive 'Jahresabschluss' (Annual Financial Statement) for Roche Pharma Aktiengesellschaft for the fiscal year 2015. It includes a balance sheet (Bilanz), profit and loss statement (Gewinn- und Verlustrechnung), and detailed notes (Anhang) covering accounting methods, asset valuations, and pension provisions. As it contains full financial statements and substantive financial analysis for a full fiscal year, it is classified as an Annual Report (10-K). FY 2015
2016-09-02 German
Jahresabschluss zum Geschäftsjahr vom 01.01.2015 bis zum 31.12.2015
Annual Report Classification · 100% confidence The document is a 'Jahresabschluss' (Annual Financial Statement) for Roche mtm laboratories AG for the fiscal year ending December 31, 2015. It contains a balance sheet (Bilanz), profit and loss statement (Gewinn- und Verlustrechnung), notes to the financial statements (Anhang), and the supervisory board report (Bericht des Aufsichtsrates). As it provides comprehensive financial statements for a full fiscal year, it is classified as an Annual Report (10-K). FY 2015
2016-08-19 German
Jahresabschluss zum Geschäftsjahr vom 01.01.2014 bis zum 31.12.2014
Annual Report Classification · 100% confidence The document is a German 'Jahresabschluss' (Annual Financial Statement) for Roche mtm laboratories AG for the fiscal year ending December 31, 2014. It includes a balance sheet (Bilanz), profit and loss statement (Gewinn- und Verlustrechnung), notes to the financial statements (Anhang), and the supervisory board report (Bericht des Aufsichtsrates). As it contains the full financial statements for a fiscal year, it is classified as an Annual Report. FY 2014
2015-08-27 German
Jahresabschluss zum Geschäftsjahr vom 01.01.2014 bis zum 31.12.2014
Interim / Quarterly Report Classification · 95% confidence The document is a German 'Jahresabschluss' (Annual Financial Statement) for Roche Pharma Aktiengesellschaft for the fiscal year ending December 31, 2014. It contains a balance sheet (Bilanz), profit and loss statement (Gewinn- und Verlustrechnung), and detailed notes (Anhang). While it is a financial report, it is a standalone statutory financial statement for a specific subsidiary rather than a consolidated group-wide Annual Report (10-K). In the context of the provided categories, this fits best as an 'Interim / Quarterly Report' (IR) equivalent for a full year, or more accurately, a standalone financial report. Given the definitions, 'IR' is the most appropriate category for comprehensive financial statements that are not the group-level 10-K. FY 2014
2015-08-21 German
Jahresabschluss zum Geschäftsjahr vom 01.01.2013 bis zum 31.12.2013
Annual Report Classification · 95% confidence The document is a German 'Jahresabschluss' (Annual Financial Statement) for Roche mtm laboratories AG for the fiscal year ending December 31, 2013. It includes a balance sheet (Bilanz), notes to the financial statements (Anhang), and the report of the supervisory board (Bericht des Aufsichtsrates). While it is not a full 10-K (which is a specific US SEC filing), it functions as the comprehensive annual financial report for a German entity. Given the provided categories, '10-K' is the most appropriate classification for a full annual financial report containing balance sheets and notes, as it represents the official yearly financial performance document. FY 2013
2014-10-13 German
Jahresabschluss zum Geschäftsjahr vom 01.01.2013 bis zum 31.12.2013
Annual Report Classification · 95% confidence The document is a comprehensive financial report for Roche Pharma AG for the fiscal year ending December 31, 2013. It includes a balance sheet (Bilanz), income statement (Gewinn- und Verlustrechnung), and detailed notes (Anhang) explaining accounting methods and specific line items. This constitutes a full annual financial report for a specific period, fitting the definition of an Interim/Quarterly Report (IR) or Annual Report (10-K). Given the German context and the specific structure of a 'Jahresabschluss' (Annual Financial Statement), it is classified as an Annual Report (10-K) as it covers the full fiscal year performance. FY 2013
2014-08-28 German

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.